{
    "nctId": "NCT06305702",
    "briefTitle": "Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer",
    "officialTitle": "Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Progression Free Survival(PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. An age of at least 18 years or older\n2. Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer\n3. Having at least one measurable lesion as defined\n4. Receiving inetetamab-based therapy in the recurrent or metastatic stage\n5. Having traceable medical history records\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Patients with other conditions deemed unsuitable for participating in this study by the researcher",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}